- Oxidation method of 4-oxo-2,3-dihydroquinoline compound
-
The invention discloses an oxidation method of a 4-oxo-2,3-dihydroquinoline compound. The method comprises the following steps: taking the 4-oxo-2,3-dihydroquinoline compound as a raw material; addingan organic solvent, an acidifying agent and an oxidizing agent; performing oxidation reaction at 50-85 DEG C; and after the reaction is finished, performing post-treatment on the reaction liquid to obtain a 4-hydroxyquinoline compound. Various raw materials used by the preparation method disclosed by the invention are simple and easy to obtain, are industrial products and have wide sources and low price; the preparation method is simple, easy to operate and high in product yield; compared with the traditional oxidation method of the 4-oxo-2,3-dihydroquinoline compound, the method disclosed bythe invention has the advantages of being more efficient and simpler in post-treatment; and the method is especially important for the industrialization of the product.
- -
-
Paragraph 0020
(2018/12/05)
-
- Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity
-
We previously reported that substituted 4-aminoquinolines with a phenyl ether substituent at the 7-position of the quinoline ring and the capability of intramolecular hydrogen bonding between the protonated amine on the side chain and a hydrogen bond acceptor on the amine's alkyl substituents exhibited potent antimalarial activity against the multidrug resistant strain P. falciparum W2. We employed a parallel synthetic method to generate diaryl ether, biaryl, and alkylaryl 4-aminoquinoline analogues in the background of a limited number of side chain variations that had previously afforded potent 4-aminoquinolines. All subsets were evaluated for their antimalarial activity against the chloroquine-sensitive strain 3D7 and the chloroquine-resistant K1 strain as well as for cytotoxicity against mammalian cell lines. While all three arrays showed good antimalarial activity, only the biaryl-containing subset showed consistently good potency against the drug-resistant K1 strain and good selectivity with regard to mammalian cytotoxicity. Overall, our data indicate that the biaryl-containing series contains promising candidates for further study.
- Hwang, Jong Yeon,Kawasuji, Takashi,Lowes, David J.,Clark, Julie A.,Connelly, Michele C.,Zhu, Fangyi,Guiguemde, W. Armand,Sigal, Martina S.,Wilson, Emily B.,Derisi, Joseph L.,Guy, R. Kiplin
-
p. 7084 - 7093
(2011/12/04)
-
- ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES
-
Aryl substituted imidazoquinoline compounds, according to formula I, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing w or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral., and neoplastic, are disclosed. formula (I): wherein: R is selected from the group consisting of alkyl, alkoxy, hydroxy, and trifluoromethyl;. N is 0 or 1; R3 is selected from the group consisting of: -Z-Ar,-Z-Ar’-Y-R4, -Z-Ar’-X-Y-R4, Z-Ar’-R5, and-Z-Ar'-X-R5; Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy; heterocyctyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino.
- -
-
-